RWJ-56110
Cat. No.：YN270724
| 产品名称: | RWJ-56110 |
| CAS No.: | 252889-88-6 |
| Chemical Name: | (αS)-N-[(1S)-3-Amino-1-[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]amino]carbonyl]amino]-3,4-difluoro-benzenepropanamide; |
| Synonyms: | RWJ56110 |
| 分子量: | 790.73 |
| 分子式: | C41H43Cl2F2N7O3 |
| SMILES: | NCCC(C(=O)NCC1=CC=CC=C1)NC(=O)C(NC(=O)NC2C=C3C(=CC=2)C(CN4CCCC4)=CN3CC5=C(Cl)C=CC=C5Cl)CC6=CC(F)=C(F)C=C6 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | RWJ-56110 是一种有效的、选择性的、拟肽抑制剂，抑制PAR-1激活和内化 (结合IC50=0.44 uM)，对 PAR-2, PAR-3 和 PAR-4 无影响。RWJ-56110 抑制由 SFLLRN-NH2 (IC50=0.16 μM) 和凝血酶 (IC50=0.34 μM) 诱导的血小板聚集，相对于 U46619 (HY-108566) 具有相当的选择性。RWJ-56110 在体内阻断血管生成和新血管的形成。RWJ-56110 诱导细胞凋亡 (apoptosis)。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Wu, C., et al.: Eur. J. Pharmacol., 546, 142-147 (2006)
Tanaka, M., et al.: J. Pharmacol. Sci., 131, 162-171 (2016)
